EMA Recommends Granting a Marketing Authorisation for Aumolertinib By Ogkologos - January 8, 2026 3 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with EGFR-mutated NSCLC Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer MOST POPULAR Countdown to 100,000 OncoLife Survivorship Care Plans: What is a Survivorship... February 25, 2021 An integral part of research September 21, 2022 Pembrolizumab Concurrent with Radiotherapy Does Not Improve the Tumour Control and... November 8, 2022 7 images that defined cancer policy in 2022 December 27, 2022 Load more HOT NEWS Palbociclib Plus Endocrine Therapy Does Not Improve PFS over Capecitabine in... FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma Women and girls in science: We won’t stop pushing for progress Living With Stage 4 Lung Cancer: How Genomic Testing Is Helping...
